-
Product Insights
NewGouty Arthritis (Gout) – Drugs In Development, 2024
Empower your strategies with our Gouty Arthritis (Gout) – Drugs In Development, 2024 report and make more profitable business decisions. Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in the blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area, and joint redness. Risk factors include obesity, high alcohol...
-
Product Insights
NewMusculoskeletal Inflammation – Drugs In Development, 2024
Empower your strategies with our Musculoskeletal Inflammation – Drugs In Development, 2024 report and make more profitable business decisions. Musculoskeletal inflammation refers to the body's response to irritation, injury, or infection affecting muscles, bones, joints, ligaments, or tendons. Conditions like arthritis, tendinitis, bursitis, or muscle strains often trigger this response. Inflammation manifests as pain, swelling, stiffness, and reduced mobility in the affected area. Causes vary—from overuse or trauma to autoimmune disorders like rheumatoid arthritis. Treatment aims to reduce inflammation and manage...
-
Product Insights
NewLymphotoxin Alpha – Drugs In Development, 2024
The Lymphotoxin Alpha pipeline drugs market research report outlays comprehensive information on the Lymphotoxin Alpha targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Immunology, Musculoskeletal Disorders, Gastrointestinal, and Infectious Disease which include indications of Rheumatoid Arthritis, Plaque Psoriasis (Psoriasis Vulgaris), Ankylosing Spondylitis (Bekhterev's Disease), Psoriatic Arthritis, Ulcerative Colitis, and Coronavirus Disease 2019 (COVID-19). It also reviews key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – prexigebersen-A in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - prexigebersen-A in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Prexigebersen-A in Solid Tumor Drug Details: Prexigebersen-A is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRX-115 in Gouty Arthritis (Gout)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRX-115 in Gouty Arthritis (Gout) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PRX-115 in Gouty Arthritis (Gout) Drug Details: PRX-115 is under development...
-
Company Profile
Protalix BioTherapeutics Inc – Company Profile
Protalix BioTherapeutics Inc (Protalix) is a biopharmaceutical company that is involved in the development and commercialization of recombinant therapeutic proteins. The company’s marketed product, Elelyso (taliglucerase alfa), is an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company also has pipeline product candidates that are intended for the treatment of cystic fibrosis, and NETs-related diseases. The company develops its proprietary pipeline of recombinant therapeutic proteins through its...
Add to Basket -
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – tulinercept
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry tulinercept Drug Details Tulinercept (etanercept biosimilar) is under development for the treatment of ulcerative...
-
Product Insights
Gouty Arthritis (Gout) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in the blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area, and joint redness. Risk factors include obesity, high alcohol intake, injury to joints, long-standing kidney disease, and high intake of foods rich in purines. The Gouty Arthritis (Gout)...
-
Product Insights
Ulcerative Colitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis – Drugs In Development, 2022, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape. Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer,...